BioWorld

April 23, 2008

Resolvyx Adds $25M to Move First Resolvin Drugs into Clinic

Gearing up to move its first two drug candidates into the clinic this year, Resolvyx Pharmaceuticals Inc. padded its bank account with a $25 million Series B round from new and existing investors. (BioWorld Today) Read More

Congress Told Foreign Plants are 'Ticking Time Bombs'

'Pseudokinase' Found Active, Without Binding Magnesium

CuraGen Sells Cancer Drug to TopoTarget for $45M

Genzyme Must File 2 BLAs for Myozyme Formulations

Theravance Cuts Staff 40%; Telavancin Inches Along

FDA Approves Cimzia for Crohn's Disease

Spectrum Shares Falls on Ozarelix Miss

ImClone, BioVex Secure SPAs For Late-Stage Cancer Studies

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...